Low Evidence
Research Overview
AOD-9604 Research for Metabolic Syndrome
An evidence-based overview of research examining AOD-9604 in the context of metabolic syndrome. This page synthesizes findings from peer-reviewed literature.
Research Summary
Unlike full-length growth hormone, AOD-9604 did not increase IGF-1 or worsen glucose metabolism in clinical trials. However, the lack of efficacy in weight loss means it offers no proven metabolic benefits.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Metabolic Syndrome
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. AOD-9604 has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.